Alpha galactosylceramide - Kyowa Hakko Kirin

Drug Profile

Alpha galactosylceramide - Kyowa Hakko Kirin

Alternative Names: AGL 582; Alpha-galactosylceramide; KRN-7000

Latest Information Update: 17 Jan 2013

Price : $50

At a glance

  • Originator Kirin Pharma Company
  • Developer Kyowa Hakko Kirin
  • Class Adjuvants; Antineoplastics; Galactosylceramides; Small molecules
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Lung cancer

Most Recent Events

  • 17 Jan 2013 Discontinued - Phase-II for Lung cancer in European Union (IV)
  • 17 Jan 2013 Discontinued - Phase-I/II for Hepatitis C in European Union (IV)
  • 17 Jan 2013 Discontinued - Phase-II for Hepatitis B in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top